EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.886
https://www.valueinhealthjournal.com/article/S1098-3015(23)04016-0/fulltext
Title :
EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04016-0&doi=10.1016/j.jval.2023.09.886
First page :
Section Title :
Open access? :
No
Section Order :
10377